Re: This Just In: Upgrades and Downgrades

Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Reply New Message

Prev Message Back To Forum Threaded View Next Message

brentie98

Rank: President [?]

Points: 5496 [?]

Votes: 21 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: This Just In: Upgrades and Downgrades

in response to

Re: This Just In: Upgrades and Downgrades

brentie98

posted on Nov 07, 2012 06:03PM

Well at least he's honest...

Big Diabetes Pharma – the winners!

In the contrast to the collective name “Big Pharma” which refers to all pharmaceutical fields I would propose a new term “Big Diabetes Pharma” – top 5 companies which monopolize the diabetes market: Novo Nordisk , Sanofi , MannKind, and the diabetes partnership of Bristol-Myers Squibb and AstraZeneca.

Only 5 companies! Amazing. Unbelievable huge profits:

The diabetes treatment business is booming. According to the Centers for Disease Control and Prevention, 25.8 million Americans are affected by diabetes. That's more than 8% of the U.S. population. S&P's Rating Services estimates that the global diabetes market will grow to 280 million people in the next 20 years, elevating sales of diabetes-related treatments from $35 billion to $58 billion.

Well, monopoly and cartel are extremely profitable systems and they are basically the main target in business wars. Those 5 companies are clearly winners! My congratulations! But what about the diabetes patients? Who cares?!